vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Terreno Realty Corp (TRNO). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $137.5M, roughly 1.2× Terreno Realty Corp). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 32.6%). Over the past eight quarters, Terreno Realty Corp's revenue compounded faster (27.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Terreno Realty Corp is a publicly traded real estate investment trust that specializes in owning, operating, and acquiring high-quality industrial real estate assets. Its portfolio mainly includes distribution warehouses and logistics facilities located in high-demand coastal U.S. metropolitan markets, serving tenants across e-commerce, last-mile delivery, retail supply chain, and light manufacturing segments.
ESPR vs TRNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $137.5M |
| Net Profit | — | $158.2M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 115.1% |
| Revenue YoY | 143.7% | 32.6% |
| Net Profit YoY | — | 107.9% |
| EPS (diluted) | $0.32 | $1.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $137.5M | ||
| Q3 25 | $87.3M | $116.2M | ||
| Q2 25 | $82.4M | $112.2M | ||
| Q1 25 | $65.0M | $110.4M | ||
| Q4 24 | $69.1M | $103.7M | ||
| Q3 24 | $51.6M | $99.6M | ||
| Q2 24 | $73.8M | $94.2M | ||
| Q1 24 | $137.7M | $85.0M |
| Q4 25 | — | $158.2M | ||
| Q3 25 | $-31.3M | $103.4M | ||
| Q2 25 | $-12.7M | $93.3M | ||
| Q1 25 | $-40.5M | $48.1M | ||
| Q4 24 | — | $76.1M | ||
| Q3 24 | $-29.5M | $36.6M | ||
| Q2 24 | $-61.9M | $35.7M | ||
| Q1 24 | $61.0M | $36.1M |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 52.5% | — |
| Q4 25 | — | 115.1% | ||
| Q3 25 | -35.9% | 88.9% | ||
| Q2 25 | -15.4% | 83.1% | ||
| Q1 25 | -62.2% | 43.6% | ||
| Q4 24 | — | 73.4% | ||
| Q3 24 | -57.2% | 36.8% | ||
| Q2 24 | -83.9% | 37.9% | ||
| Q1 24 | 44.3% | 42.4% |
| Q4 25 | $0.32 | $1.54 | ||
| Q3 25 | $-0.16 | $1.00 | ||
| Q2 25 | $-0.06 | $0.90 | ||
| Q1 25 | $-0.21 | $0.47 | ||
| Q4 24 | $-0.14 | $0.78 | ||
| Q3 24 | $-0.15 | $0.37 | ||
| Q2 24 | $-0.33 | $0.37 | ||
| Q1 24 | $0.34 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $25.0M |
| Total DebtLower is stronger | — | $943.3M |
| Stockholders' EquityBook value | $-302.0M | $4.1B |
| Total Assets | $465.9M | $5.4B |
| Debt / EquityLower = less leverage | — | 0.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $25.0M | ||
| Q3 25 | $92.4M | $26.2M | ||
| Q2 25 | $86.1M | $128.4M | ||
| Q1 25 | $114.6M | $156.5M | ||
| Q4 24 | $144.8M | $18.1M | ||
| Q3 24 | $144.7M | $243.7M | ||
| Q2 24 | $189.3M | $182.0M | ||
| Q1 24 | $226.6M | $649.6M |
| Q4 25 | — | $943.3M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $742.4M | ||
| Q1 25 | — | $741.9M | ||
| Q4 24 | — | $823.4M | ||
| Q3 24 | — | $672.2M | ||
| Q2 24 | — | $772.0M | ||
| Q1 24 | — | $771.8M |
| Q4 25 | $-302.0M | $4.1B | ||
| Q3 25 | $-451.4M | $4.0B | ||
| Q2 25 | $-433.5M | $3.9B | ||
| Q1 25 | $-426.2M | $3.9B | ||
| Q4 24 | $-388.7M | $3.7B | ||
| Q3 24 | $-370.2M | $3.6B | ||
| Q2 24 | $-344.2M | $3.4B | ||
| Q1 24 | $-294.3M | $3.4B |
| Q4 25 | $465.9M | $5.4B | ||
| Q3 25 | $364.0M | $5.3B | ||
| Q2 25 | $347.1M | $5.0B | ||
| Q1 25 | $324.0M | $4.9B | ||
| Q4 24 | $343.8M | $4.8B | ||
| Q3 24 | $314.1M | $4.6B | ||
| Q2 24 | $352.3M | $4.5B | ||
| Q1 24 | $373.1M | $4.4B |
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $271.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $271.9M | ||
| Q3 25 | $-4.3M | $79.5M | ||
| Q2 25 | $-31.4M | $60.6M | ||
| Q1 25 | $-22.6M | $61.4M | ||
| Q4 24 | $-35.0M | $232.7M | ||
| Q3 24 | $-35.3M | $70.0M | ||
| Q2 24 | $-7.2M | $64.3M | ||
| Q1 24 | $53.8M | $47.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | 1.80× | ||
| Q1 24 | 0.88× | 1.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TRNO
| Disposal Group Disposed Of By Sale Not Discontinued Operations | $109.5M | 80% |
| Other | $23.8M | 17% |
| At Market Equity Offering Program500Million | $4.1M | 3% |
